Liver Cirrhosis – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 9 PAGES: 56

More Info
									                    Liver Cirrhosis – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1843IDB
                                                                                              Publication Date: April 2012




Liver Cirrhosis – Pipeline Review, H1 2012                                                    GMDHC1843IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Liver Cirrhosis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Liver Cirrhosis Overview..................................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Liver Cirrhosis .................................................................................................................... 8
Liver Cirrhosis Therapeutics under Development by Companies ..................................................................................................... 10
Liver Cirrhosis Therapeutics under Investigation by Universities/Institutes ...................................................................................... 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Pre-Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Liver Cirrhosis Therapeutics – Products under Development by Companies ................................................................................... 17
Liver Cirrhosis Therapeutics – Products under Investigation by Universities/Institutes .................................................................... 18
Companies Involved in Liver Cirrhosis Therapeutics Development.................................................................................................. 19
    Stelic Institute & Co. .................................................................................................................................................................... 19
    Stempeutics Research Private Limited ........................................................................................................................................ 20
Liver Cirrhosis – Therapeutics Assessment ..................................................................................................................................... 21
    Assessment by Monotherapy Products ....................................................................................................................................... 21
    Assessment by Combination Products ........................................................................................................................................ 22
    Assessment by Route of Administration ...................................................................................................................................... 23
    Assessment by Molecule Type .................................................................................................................................................... 25
Drug Profiles..................................................................................................................................................................................... 27
    STNM04 - Drug Profile ................................................................................................................................................................ 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Sorafenib - Drug Profile ............................................................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Autologous CD133 + Stem Cells - Drug Profile ........................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Torisel - Drug Profile.................................................................................................................................................................... 31



Liver Cirrhosis – Pipeline Review, H1 2012                                                                                                         GMDHC1843IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Liver Cirrhosis – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 31
        Mechanism of Action ............................................................................................................................................................... 31
        R&D Progress ......................................................................................................................................................................... 31
    Lenograstim + Haematopoietic Stem Cells - Drug Profile............................................................................................................ 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    Nobelzin - Drug Profile ................................................................................................................................................................ 33
        Product Description................................................................................................................................................................. 33
        Mechanism of Action ............................................................................................................................................................... 33
        R&D Progress ......................................................................................................................................................................... 33
    Bone Marrow Derived CD133+ Stem Cells Transplantation - Drug Profile .................................................................................. 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    Umbilical Cord Mesenchymal Stem Cells - Drug Profile .............................................................................................................. 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    Allogenic Bone Marrow Stem Cells Transplant - Drug Profile ..................................................................................................... 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Autologous Bone Marrow Mesenchymal Stem Cells Transplant - Drug Profile ........................................................................... 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Umbilical Cord Mesenchymal Stem Cells - Drug Profile .............................................................................................................. 38
        Product Description...
								
To top